[1] NARITA T, HOSOBA M, KAKEI M,et al. Increased urinary excretions of immunoglobulin g, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes[J]. Diabetes Care,2006,29(1):142-144.
[2] 周红梅. 糖尿病肾病患者尿蛋白与尿微量蛋白的检验及意义评定[J].糖尿病新世界,2018,21(16):177-178.
[3] 朱晓英,施笑娅,徐象威.尿微量蛋白、胱抑素C、糖化血红蛋白及晚期糖基化终末产物对糖尿病早期肾损伤的应用评价[J].中国现代医生,2017,55(33):116-120.
[4] TYERS M, MANN M.From genomics to proteomics[J]. Nature, 2003, 422(6928):193-197.
[5] THONGBOONKERD V, BARATI M T, MCLEISH K R, et al. Proteomics and diabetic nephropathy[J]. Contrib Nephrol, 2004, 141:142-154.
[6] MERCHANT M L, KLEIN J B.Proteomic and diabetic nephropathy[J]. Semin Nephrol, 2007, 27(6): 627-636.
[7] 卫生部疾病控制司,中华医学会糖尿病学分会.中国糖尿病防治指南[M].北京:中华糖尿病杂志社出版,2003:9-11.
[8] 安玉,徐峰,乐伟波,等.糖尿病肾病病理分型临床应用的评估[J].肾脏病与透析移植杂志,2013,22(4):301-308.
[9] MISE K, HOSHINO J, UBARA Y, et al.Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy[J]. Nephrol Dial Transplant, 2014, 29(1): 109-118.
[10] BONVENTRE J V.The kidney proteome: a hint of things to come[J]. Kidney Int, 2002, 62(4): 1470-1471.
[11] STERNLICHT H, BAKRIS G L.Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?[J]. Blood Purif, 2016, 41(1-3): 139-143.
[12] LEWIS G, MAXWELL A P.Risk factor control is key in diabetic nephropathy[J]. Practitioner, 2014, 258(1768): 13-17, 2.
[13] 陈艳蓉,兰小鹏.SELDI-TOFMS室内质量控制的初步研究[J].实用医学杂志,2009,25(12):2074-2076. |